4.5389
3.43%
-0.1211
Schlusskurs vom Vortag:
$4.66
Offen:
$4.66
24-Stunden-Volumen:
129.90K
Relative Volume:
0.07
Marktkapitalisierung:
$780.00M
Einnahmen:
$25.55M
Nettoeinkommen (Verlust:
$-341.97M
KGV:
-1.6873
EPS:
-2.69
Netto-Cashflow:
$-304.44M
1W Leistung:
-19.64%
1M Leistung:
-30.02%
6M Leistung:
-40.48%
1J Leistung:
-43.47%
Relay Therapeutics Inc Stock (RLAY) Company Profile
Firmenname
Relay Therapeutics Inc
Sektor
Branche
Telefon
617-370-8837
Adresse
399 BINNEY STREET, CAMBRIDGE
Vergleichen Sie RLAY mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
RLAY | 4.54 | 780.00M | 25.55M | -341.97M | -304.44M | -2.69 |
VRTX | 446.82 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.18 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 585.10 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.38 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.30 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Relay Therapeutics Inc Stock (RLAY) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-04-20 | Hochstufung | Jefferies | Underperform → Hold |
2023-04-19 | Hochstufung | Raymond James | Outperform → Strong Buy |
2023-04-13 | Eingeleitet | Raymond James | Outperform |
2023-02-03 | Eingeleitet | Oppenheimer | Outperform |
2022-09-30 | Eingeleitet | Barclays | Equal Weight |
2022-09-02 | Eingeleitet | Stifel | Buy |
2022-06-06 | Eingeleitet | Jefferies | Underperform |
2022-02-01 | Eingeleitet | Berenberg | Buy |
2021-07-21 | Eingeleitet | BofA Securities | Buy |
2020-12-15 | Bestätigt | H.C. Wainwright | Buy |
2020-12-08 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-11-05 | Eingeleitet | H.C. Wainwright | Buy |
2020-08-10 | Eingeleitet | Cowen | Outperform |
2020-08-10 | Eingeleitet | Goldman | Buy |
2020-08-10 | Eingeleitet | Guggenheim | Buy |
2020-08-10 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Relay Therapeutics Inc Aktie (RLAY) Neueste Nachrichten
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround - Yahoo Finance
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround - Yahoo Finance
First Turn Management LLC Buys New Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.8% – Here’s What Happened - Defense World
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8%Time to Sell? - MarketBeat
(RLAY) Trading Report - Stock Traders Daily
Relay Therapeutics stock hits 52-week low at $5.59 - Investing.com India
Relay Therapeutics stock hits 52-week low at $5.59 By Investing.com - Investing.com UK
Analyzing Valneva (NASDAQ:VALN) and Relay Therapeutics (NASDAQ:RLAY) - Defense World
NKGen Biotech (NYSE:NKGN) versus Relay Therapeutics (NASDAQ:RLAY) Financial Contrast - Defense World
Relay Therapeutics' SWOT analysis: PI3K inhibitor progress fuels stock potential - Investing.com
HC Wainwright Forecasts Strong Price Appreciation for Relay Therapeutics (NASDAQ:RLAY) Stock - Defense World
Research Analysts Offer Predictions for RLAY FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for RLAY Issued By Leerink Partnrs - Defense World
Relay Therapeutics (NASDAQ:RLAY) Given New $20.00 Price Target at HC Wainwright - MarketBeat
Relay Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
RLAYRelay Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Relay Therapeutics Reports Q3 2024 Results and Advances - TipRanks
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Relay Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Where are the Opportunities in (RLAY) - Stock Traders Daily
Relay Therapeutics (RLAY) to Release Earnings on Wednesday - MarketBeat
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts - Investing.com Australia
Relay Therapeutics stock hits 52-week low at $5.7 amid market shifts By Investing.com - Investing.com South Africa
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 - The Manila Times
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, - EIN News
Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy - Barchart
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses - Yahoo Finance
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Several Relay Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com Canada
Relay Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase By Investing.com - Investing.com South Africa
Financial Snapshot: Analyzing Relay Therapeutics Inc (RLAY)’s Key Ratio Metrics - The Dwinnex
Relay Therapeutics, Inc. (NASDAQ:RLAY) Short Interest Update - MarketBeat
How did Relay Therapeutics Inc (RLAY) fare last session? - US Post News
Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright - MarketBeat
Relay Therapeutics stock holds price target on FDA approval By Investing.com - Investing.com UK
Relay Therapeutics Inc (RLAY) receives a Buy rating from Jefferies - Knox Daily
Finanzdaten der Relay Therapeutics Inc-Aktie (RLAY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Relay Therapeutics Inc-Aktie (RLAY) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Catinazzo Thomas | Chief Financial Officer |
Oct 28 '24 |
Sale |
6.06 |
6,802 |
41,220 |
306,391 |
Catinazzo Thomas | Chief Financial Officer |
Oct 29 '24 |
Sale |
5.95 |
2,300 |
13,685 |
304,091 |
Bergstrom Donald A | President, R&D |
Oct 28 '24 |
Sale |
6.06 |
2,688 |
16,289 |
520,745 |
Adams Brian | Chief Legal Officer |
Oct 28 '24 |
Sale |
6.06 |
1,632 |
9,890 |
321,907 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):